Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Histopathology. 2021 Apr;78(5):710-716. doi: 10.1111/his.14278. Epub 2020 Dec 8.
The faecal immunochemical test (FIT) is used every 2 years to screen average-risk British Columbians aged 50-74 years, with follow-up colonoscopy for positive results. Non-screen-detected colorectal adenocarcinomas are defined as those detected within 25 months following a negative FIT. We aimed to more clearly characterise these malignancies.
A medical chart and focused pathology review of colorectal malignancies from 926 individuals who completed FIT in the British Columbia Colon Screening Program in 2014, and whose pathology reports were available for review, was conducted. This cohort was divided into two groups: individuals with colorectal adenocarcinomas diagnosed following a positive FIT (screen-detected) and individuals with colorectal adenocarcinoma diagnosed within 25 months of a negative FIT (FIT-interval cancers). Rates of clinically relevant pathological parameters, as outlined in the American Joint Committee on Cancer (AJCC), 8th edition, were compared between the screen-detected and FIT-interval cancer groups. A total of 876 screen-detected and 50 FIT-interval cancers were identified. FIT-interval cancers exhibited higher rates of high-grade differentiation (including poorly differentiated and undifferentiated cases; P < 0.01) and aggressive histotype (signet ring cell and mucinous carcinomas; P < 0.01) than did screen-detected cancers after Bonferroni correction. Colorectal adenocarcinoma diagnosed after a negative FIT may therefore be associated with worse prognostic determinants than screen-detected cancers.
FIT-interval cancers are associated with high-risk pathological features; the possibility that more aggressive, fast-growing lesions which arise in the interval after truly negative FITs cannot be ruled out. Further study of a larger cohort of FIT-interval cancers controlling for interaction among the different pathologic parameters will be undertaken.
粪便免疫化学检测(FIT)用于筛查每两年一次的 50-74 岁不列颠哥伦比亚省平均风险人群,阳性结果则进行后续结肠镜检查。非筛查检出的结直肠腺癌定义为在阴性 FIT 后 25 个月内检出的腺癌。我们旨在更清楚地描述这些恶性肿瘤。
对 2014 年在不列颠哥伦比亚省结肠筛查计划中完成 FIT 且可获得病理报告的 926 名个体的结直肠恶性肿瘤的病历和重点病理复习进行了分析。该队列分为两组:FIT 阳性(筛查检出)后诊断出的结直肠腺癌患者和阴性 FIT 后 25 个月内诊断出的结直肠腺癌患者(FIT 间隔期癌症)。比较了两组中美国癌症联合委员会(AJCC)第 8 版中概述的具有临床意义的病理参数的发生率。共发现 876 例筛查检出和 50 例 FIT 间隔期癌症。经 Bonferroni 校正后,FIT 间隔期癌症的高级别分化(包括低分化和未分化病例;P<0.01)和侵袭性组织学类型(印戒细胞癌和黏液癌;P<0.01)发生率高于筛查检出癌症。因此,阴性 FIT 后诊断的结直肠腺癌可能与预后不良的决定因素有关。
FIT 间隔期癌症与高危病理特征相关;不能排除 FIT 后真正阴性间隔期出现更具侵袭性、生长更快的病变的可能性。将对更大的 FIT 间隔期癌症队列进行进一步研究,以控制不同病理参数之间的相互作用。